Treatment :

The Best approach in malaria treatment is diagnosis and treatment on the same day.

A. In High Risk Areas (Pf.Predominant And Drug Resistance Areas)

i) Presumptive Treatment of all Suspected clinical Malaria Cases:

Day 1

Tab.Chloroquine - 10 mg/kg body weight (bw) (600 mg adult dose)

Tab.Priomaquine - 0.75 mg/kg bw 45 mg adult dose)


Day 2      Tab.Chloroquine - 10 mg/kg bw (600 mg adult dose)

Day 3      Tab.Chloroquine - 5 mg/kg bw (300 mg adult dose)

ii) Radical Treatment after Microscopic confirmation of Species:

P.vivax - Tab.Primaquine 0.25 mg/kg bw (15 mg adult dose) daily for 5 days.

P.falciparam - No further treatment required.

iii) In Chloroquine Resistant P.falciparam Cases/Area

Single dose of 25 mg/kg bw tab.Sulfalenes/Sulfadoxine and 1.25 mg/kg bw Pyrimethamine combination (3 tabs adult) with tab.Primaquine 0.75 mg/kg bw

B. In Low Risk Areas

i) Presumptive Treatment

Day1 Tab.Chloroquine 10 mg/kg body weight (bw) (600 mg adult state dose)

ii) Radical Treatment after Confirmation of Species

P. vivax Tab.Chloroquine 10 mg/kg bw single dose and tab.Primaquine 0.25 mg/kg bw daily for 5 days

P.faliciparam- Tab.Chloroquine 10 mg/kg bw plus tab.Primaquine 0.75 mg/kg bw single dose

C. Severe & Compicated Malaria Cases to be Hospitalized for the Treatment

i) Choice of antimalarial is quinine injection preferably, 10 mg per kg bw i/v drip in 5% dextrose saline to be run over 4 hours, 8 hourly. Switch over to oral dose as early as possible and total duration of treatment should be 7 dyas.

ii) Injectable form of artemisinin derivatives may be used for severe and complicated malaria only.

D. Other information:

i) Tab.Mefloquine is to be used only in Pf cases having proven resistance to chloroquine. Drug may be obtained from drug depots after producing prescription given by registered medical specialist and lab report confirming of having blood slide positive for asexual stage of Pf.parasite. ii) Sulfa-Pyrimethamine combination is not effective in P.vivax cases.

Note : Primaquine is not to be given to pregnant women, infants and Glucose 6 Phosphate Deficient Persons

Source : NMAP
Last Updated on:06/05/2014